WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000062775) COMPOSITIONS AND METHODS FOR INCREASING THE BIOAVAILABILITY OF LACTONE RING CONTAINING DRUGS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/062775    International Application No.:    PCT/US2000/009989
Publication Date: 26.10.2000 International Filing Date: 14.04.2000
Chapter 2 Demand Filed:    24.10.2000    
IPC:
A61K 31/405 (2006.01), A61K 31/47 (2006.01), A61K 31/55 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; 3003 South State Street, Ann Arbor, MI 48109-1280 (US) (For All Designated States Except US).
LA DU, Bert, N. [US/US]; (US) (For US Only).
BILLECKE, Scott, s. [US/US]; (US) (For US Only).
COUNSEL, Raymond [US/US]; (US) (For US Only)
Inventors: LA DU, Bert, N.; (US).
BILLECKE, Scott, s.; (US).
COUNSEL, Raymond; (US)
Agent: CARROLL, Peter, G.; Medlen & Carroll, LLP, Suite 350, 101 Howard Street, San Francisco, CA 94105 (US)
Priority Data:
60/130,051 19.04.1999 US
Title (EN) COMPOSITIONS AND METHODS FOR INCREASING THE BIOAVAILABILITY OF LACTONE RING CONTAINING DRUGS
(FR) COMPOSITIONS ET METHODES DESTINEES A AUGMENTER LA BIODISPONIBILITE DE MEDICAMENTS CONTENANT UN NOYAU DE LACTONE
Abstract: front page image
(EN)Compositions and methods are described for increasing the bioavailability of drugs, and in particular, drugs and prodrugs containing lactone structures which are hydrolyzed to open forms (carboxylic acids and alcohols) by serum and tissue paraoxonase. Inhibitors of paraoxonase (e.g. lactams) are co-administered with such drugs, thereby preventing paraoxonase from acting on these lactone substrates. Such inhibitors are particularly suitable in conjunction with the administration of lovastatin, simvastatin or mevastatin.
(FR)L'invention concerne des compositions et des méthodes destinées à augmenter la biodisponibilité de médicaments et, en particulier, de médicaments ou de promédicaments contenant des structures de lactone hydrolysées en formes ouvertes (acides carboxyliques et alcools) par paraoxonase sérique et tissulaire. Des inhibiteurs de paraoxonase (par exemple des lactames) sont coadministrés avec ces médicaments, prévenant ainsi la paraoxonase d'agir sur ces substrats de lactone. Ces inhibiteurs sont particulièrement adaptés conjointement avec l'administration de lovastatine, de simvastatine ou de mévastatine.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)